These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 2749590)
1. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590 [TBL] [Abstract][Full Text] [Related]
2. Homozygous variant of antithrombin III: AT III Fontainebleau. Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688 [TBL] [Abstract][Full Text] [Related]
3. Antithrombin III Alger: a new homozygous AT III variant. Fischer AM; Cornu P; Sternberg C; Mériane F; Dautzenberg MD; Chafa O; Beguin S; Desnos M Thromb Haemost; 1986 Apr; 55(2):218-21. PubMed ID: 3715788 [TBL] [Abstract][Full Text] [Related]
4. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity. de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409 [TBL] [Abstract][Full Text] [Related]
5. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding. Tripodi A; Krachmalnicoff A; Mannucci PM Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966 [TBL] [Abstract][Full Text] [Related]
6. Homozygous or compound heterozygous qualitative antithrombin III deficiency. Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):335-7. PubMed ID: 7971256 [TBL] [Abstract][Full Text] [Related]
7. Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity. Howarth DJ; Samson D; Stirling Y; Seghatchian MJ Thromb Haemost; 1985 Jun; 53(3):314-9. PubMed ID: 4049307 [TBL] [Abstract][Full Text] [Related]
8. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin. Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187 [TBL] [Abstract][Full Text] [Related]
9. Antithrombin III Avranches, a new variant with defective serine-protease inhibition--comparison with antithrombin III Charleville. Aiach M; Roncato M; Chadeuf G; Dezellus P; Capron L; Fiessinger JN Thromb Haemost; 1988 Aug; 60(1):94-6. PubMed ID: 3187951 [TBL] [Abstract][Full Text] [Related]
10. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391 [TBL] [Abstract][Full Text] [Related]
11. Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis. Sakuragawa N; Takahashi K; Kondo S; Koide T Thromb Res; 1983 Jul; 31(2):305-17. PubMed ID: 6636045 [TBL] [Abstract][Full Text] [Related]
12. Antithrombin III deficiency. Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A Rom J Intern Med; 1994; 32(2):119-27. PubMed ID: 7920326 [TBL] [Abstract][Full Text] [Related]
13. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver"). Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602 [TBL] [Abstract][Full Text] [Related]
14. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence. Bohner J; von Pape KW; Blaurock M Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789 [TBL] [Abstract][Full Text] [Related]
15. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women]. Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806 [TBL] [Abstract][Full Text] [Related]
16. AT III Barcelona: a familial quantitative-qualitative AT III deficiency. Grau E; Fontcuberta J; Félez J; de Diego I; Soto R; Rutllant ML Thromb Haemost; 1988 Feb; 59(1):13-7. PubMed ID: 3363529 [TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. Jørgensen M; Petersen LC; Thorsen S J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440 [TBL] [Abstract][Full Text] [Related]
18. Biochemical and functional study of antithrombin III in newborn infants. McDonald MM; Hathaway WE; Reeve EB; Leonard BD Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806 [TBL] [Abstract][Full Text] [Related]
19. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin. Shimotori T; Sakuragawa N Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909 [TBL] [Abstract][Full Text] [Related]
20. Abnormal properties and behaviors of antithrombin III found in a thrombophilic patient: defective biological functions and dissimilar antigenic determinants. Murayama H; Matsuda M Thromb Haemost; 1986 Oct; 56(2):165-71. PubMed ID: 3101219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]